Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Antares Pharma, a company that focuses on self-injection delivery technologies and topical gel-based pharmaceutical products, has reported revenues of $3.34m for the first quarter ended Mar 31, 2010, an increase of 42.2%, compared to $2.34m for the comparable period in 2009.
Subscribe to our email newsletter
Antares Pharma has posted a net loss of $1.6m for the first quarter 2010, or $0.02 per diluted share, compared to $2.78m, or $0.04 per diluted share, for the comparable period in 2009. Operating loss was $1.58m, compared to $2.58 for the comparable period in 2009.
Paul Wotton, president and CEO of Antares Pharma, said: “We are pleased with the strong results for the first quarter and expect our momentum to continue throughout 2010 as we execute against our strategic plan. Since launch, sales of our Tjet needle-free injector system used with Tev-Tropin have exceeded our expectations.
“Efforts with Teva regarding the commercial development of additional products continue to progress. We also look forward to announcing results for our ongoing study of Anturol in the thirdquarter of 2010.”